Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women

Jonathan V. Todd, Stephen R. Cole, David A. Wohl, Ross J. Simpson, Michele Jonsson Funk, M. Alan Brookhart, Jennifer Cocohoba, Daniel Merenstein, Anjali Sharma, Jason Lazar, Joel Milam, Mardge Cohen, Stephen Gange, Tené T. Lewis, Greer Burkholder, Adaora A. Adimora

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Increased life expectancy of persons living with HIV infection receiving antiretroviral therapy heightens the importance of preventing and treating chronic comorbidities such as cardiovascular disease. While guidelines have increasingly advocated more aggressive use of statins for low-density lipoprotein (LDL) cholesterol reduction, it is unclear whether people with HIV, especially women, are receiving statins when indicated, and whether their HIV disease is a factor in access. We assessed the cumulative incidence of statin use after an indication in the Women's Interagency HIV Study (WIHS), from 2000 to 2014. Additionally, we used weighted proportional hazards regression to estimate the effect of HIV serostatus on the time to initiation of a statin after an indication. Cumulative incidence of statin use 5 years after an indication was low: 38% in HIV-seropositive women and 30% in HIV-seronegative women. Compared to HIV-seronegative women, the weighted hazard ratio for initiation of a statin for HIV-seropositive women over 5 years was 0.94 [95% confidence interval (CI) 0.62, 1.43]. Applying the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines increased the proportion of HIV-seropositive women with a statin indication from 16% to 45%. Clinicians treating HIV-seropositive women should consider more aggressive management of the dyslipidemia often found in this population.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalAIDS Patient Care and STDs
Volume31
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV
Guidelines
Incidence
Dyslipidemias
Life Expectancy
LDL Cholesterol
HIV Infections
Comorbidity
Cardiovascular Diseases
Confidence Intervals

Keywords

  • cardiovascular disease
  • human immunodeficiency virus
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • lipids
  • statins
  • women's health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Todd, J. V., Cole, S. R., Wohl, D. A., Simpson, R. J., Jonsson Funk, M., Brookhart, M. A., ... Adimora, A. A. (2017). Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. AIDS Patient Care and STDs, 31(11), 447-454. https://doi.org/10.1089/apc.2017.0145

Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. / Todd, Jonathan V.; Cole, Stephen R.; Wohl, David A.; Simpson, Ross J.; Jonsson Funk, Michele; Brookhart, M. Alan; Cocohoba, Jennifer; Merenstein, Daniel; Sharma, Anjali; Lazar, Jason; Milam, Joel; Cohen, Mardge; Gange, Stephen; Lewis, Tené T.; Burkholder, Greer; Adimora, Adaora A.

In: AIDS Patient Care and STDs, Vol. 31, No. 11, 01.11.2017, p. 447-454.

Research output: Contribution to journalArticle

Todd, JV, Cole, SR, Wohl, DA, Simpson, RJ, Jonsson Funk, M, Brookhart, MA, Cocohoba, J, Merenstein, D, Sharma, A, Lazar, J, Milam, J, Cohen, M, Gange, S, Lewis, TT, Burkholder, G & Adimora, AA 2017, 'Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women', AIDS Patient Care and STDs, vol. 31, no. 11, pp. 447-454. https://doi.org/10.1089/apc.2017.0145
Todd JV, Cole SR, Wohl DA, Simpson RJ, Jonsson Funk M, Brookhart MA et al. Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. AIDS Patient Care and STDs. 2017 Nov 1;31(11):447-454. https://doi.org/10.1089/apc.2017.0145
Todd, Jonathan V. ; Cole, Stephen R. ; Wohl, David A. ; Simpson, Ross J. ; Jonsson Funk, Michele ; Brookhart, M. Alan ; Cocohoba, Jennifer ; Merenstein, Daniel ; Sharma, Anjali ; Lazar, Jason ; Milam, Joel ; Cohen, Mardge ; Gange, Stephen ; Lewis, Tené T. ; Burkholder, Greer ; Adimora, Adaora A. / Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. In: AIDS Patient Care and STDs. 2017 ; Vol. 31, No. 11. pp. 447-454.
@article{3cd9817861b448218bd9228186fd46a9,
title = "Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women",
abstract = "Increased life expectancy of persons living with HIV infection receiving antiretroviral therapy heightens the importance of preventing and treating chronic comorbidities such as cardiovascular disease. While guidelines have increasingly advocated more aggressive use of statins for low-density lipoprotein (LDL) cholesterol reduction, it is unclear whether people with HIV, especially women, are receiving statins when indicated, and whether their HIV disease is a factor in access. We assessed the cumulative incidence of statin use after an indication in the Women's Interagency HIV Study (WIHS), from 2000 to 2014. Additionally, we used weighted proportional hazards regression to estimate the effect of HIV serostatus on the time to initiation of a statin after an indication. Cumulative incidence of statin use 5 years after an indication was low: 38{\%} in HIV-seropositive women and 30{\%} in HIV-seronegative women. Compared to HIV-seronegative women, the weighted hazard ratio for initiation of a statin for HIV-seropositive women over 5 years was 0.94 [95{\%} confidence interval (CI) 0.62, 1.43]. Applying the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines increased the proportion of HIV-seropositive women with a statin indication from 16{\%} to 45{\%}. Clinicians treating HIV-seropositive women should consider more aggressive management of the dyslipidemia often found in this population.",
keywords = "cardiovascular disease, human immunodeficiency virus, hydroxymethylglutaryl-CoA reductase inhibitors, lipids, statins, women's health",
author = "Todd, {Jonathan V.} and Cole, {Stephen R.} and Wohl, {David A.} and Simpson, {Ross J.} and {Jonsson Funk}, Michele and Brookhart, {M. Alan} and Jennifer Cocohoba and Daniel Merenstein and Anjali Sharma and Jason Lazar and Joel Milam and Mardge Cohen and Stephen Gange and Lewis, {Ten{\'e} T.} and Greer Burkholder and Adimora, {Adaora A.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1089/apc.2017.0145",
language = "English (US)",
volume = "31",
pages = "447--454",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women

AU - Todd, Jonathan V.

AU - Cole, Stephen R.

AU - Wohl, David A.

AU - Simpson, Ross J.

AU - Jonsson Funk, Michele

AU - Brookhart, M. Alan

AU - Cocohoba, Jennifer

AU - Merenstein, Daniel

AU - Sharma, Anjali

AU - Lazar, Jason

AU - Milam, Joel

AU - Cohen, Mardge

AU - Gange, Stephen

AU - Lewis, Tené T.

AU - Burkholder, Greer

AU - Adimora, Adaora A.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Increased life expectancy of persons living with HIV infection receiving antiretroviral therapy heightens the importance of preventing and treating chronic comorbidities such as cardiovascular disease. While guidelines have increasingly advocated more aggressive use of statins for low-density lipoprotein (LDL) cholesterol reduction, it is unclear whether people with HIV, especially women, are receiving statins when indicated, and whether their HIV disease is a factor in access. We assessed the cumulative incidence of statin use after an indication in the Women's Interagency HIV Study (WIHS), from 2000 to 2014. Additionally, we used weighted proportional hazards regression to estimate the effect of HIV serostatus on the time to initiation of a statin after an indication. Cumulative incidence of statin use 5 years after an indication was low: 38% in HIV-seropositive women and 30% in HIV-seronegative women. Compared to HIV-seronegative women, the weighted hazard ratio for initiation of a statin for HIV-seropositive women over 5 years was 0.94 [95% confidence interval (CI) 0.62, 1.43]. Applying the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines increased the proportion of HIV-seropositive women with a statin indication from 16% to 45%. Clinicians treating HIV-seropositive women should consider more aggressive management of the dyslipidemia often found in this population.

AB - Increased life expectancy of persons living with HIV infection receiving antiretroviral therapy heightens the importance of preventing and treating chronic comorbidities such as cardiovascular disease. While guidelines have increasingly advocated more aggressive use of statins for low-density lipoprotein (LDL) cholesterol reduction, it is unclear whether people with HIV, especially women, are receiving statins when indicated, and whether their HIV disease is a factor in access. We assessed the cumulative incidence of statin use after an indication in the Women's Interagency HIV Study (WIHS), from 2000 to 2014. Additionally, we used weighted proportional hazards regression to estimate the effect of HIV serostatus on the time to initiation of a statin after an indication. Cumulative incidence of statin use 5 years after an indication was low: 38% in HIV-seropositive women and 30% in HIV-seronegative women. Compared to HIV-seronegative women, the weighted hazard ratio for initiation of a statin for HIV-seropositive women over 5 years was 0.94 [95% confidence interval (CI) 0.62, 1.43]. Applying the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines increased the proportion of HIV-seropositive women with a statin indication from 16% to 45%. Clinicians treating HIV-seropositive women should consider more aggressive management of the dyslipidemia often found in this population.

KW - cardiovascular disease

KW - human immunodeficiency virus

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - lipids

KW - statins

KW - women's health

UR - http://www.scopus.com/inward/record.url?scp=85032704275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032704275&partnerID=8YFLogxK

U2 - 10.1089/apc.2017.0145

DO - 10.1089/apc.2017.0145

M3 - Article

C2 - 29087746

AN - SCOPUS:85032704275

VL - 31

SP - 447

EP - 454

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 11

ER -